About glucotrack inc - GCTK
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.
GCTK At a Glance
GlucoTrack, Inc.
301 Route 17 North
Rutherford, New Jersey 07070
| Phone | 1-201-842-7715 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -19,388,000.00 | |
| Sector | Health Technology | Employees | 15 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GCTK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.246 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.096 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -2.247 |
GCTK Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,292,533.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GCTK Liquidity
| Current Ratio | 1.606 |
| Quick Ratio | 1.606 |
| Cash Ratio | 1.547 |
GCTK Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -281.598 |
| Return on Equity | N/A |
| Return on Total Capital | -309.021 |
| Return on Invested Capital | N/A |
GCTK Capital Structure
| Total Debt to Total Equity | 121.853 |
| Total Debt to Total Capital | 54.925 |
| Total Debt to Total Assets | 43.965 |
| Long-Term Debt to Equity | 8.345 |
| Long-Term Debt to Total Capital | 3.762 |